Global X CleanTech vs State Street SPDR S&P Biotech ETF — how do they compare? Global X CleanTech trades at $55.45 (market cap $24.57M), while State Street SPDR S&P Biotech ETF trades at $153.1 (market cap $10.11B). The key difference: State Street SPDR S&P Biotech ETF is far larger — about 411.5× Global X CleanTech's market cap, and State Street SPDR S&P Biotech ETF is trading nearer its 52-week high, Global X CleanTech nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Global X CleanTech for 42 Days and State Street SPDR S&P Biotech ETF for 37 Days on average.
| CTEC | XBI | |
|---|---|---|
Market Cap | $24.57M | $10.11B |
Volume | 1,220 | 12,903,266 |
Sector | Sector/Thematic | Broad Market / Factor |
52-Week High | $78.11 | $169.55 |
52-Week Low | $50.82 | $104.99 |
Typical Hold Time | 42 Days | 37 Days |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
XBI trades at $153.34, up 2.07% today, but faces bearish technical signals with 17 sell indicators versus 4 buys. The ETF's modified equal-weight structure provides exposure to over 150 biotech companies, benefiting from recent M&A activity and positive clinical trial catalysts. Current price sits near resistance at $154, with support at $147.
Biotech sector optimism is growing with cancer vaccine breakthroughs and improved capital access, though XBI's 0.35% expense ratio is higher than broader healthcare ETFs. Key risks include sector volatility and regulatory uncertainty, while analyst consensus remains neutral with 100% hold rating.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
CTEC invests in companies at the forefront of the clean technology industry. It focuses on disruptive innovations in renewable energy production, energy storage, smart grids, and energy efficiency, with top holdings like Enphase and First Solar.
Read more on CTEC →XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →